Changes to the Code
S. 2513 · OTC Monograph Drug User Fee Transparency Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
21 U.S.C. § 379j–73 Reauthorization; reporting requirements
4 changes the bill asks for here, 1 carried out
- Not carried out:
by striking Beginning with and inserting the following:(1) In general.— Beginning with;
§ 379j–73(a) already has provisions of its own, so its opening words can't simply become the first of them.
Technical detail
/us/usc/t21/s379j–73/a has provisions already, so its words can't become the first - Not carried out:
by striking
section 3861(b)
and insertingsection 3861
; and“section 3861(b)” isn't in § 379j–73(a) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“section 3861(b)” not found in /us/usc/t21/s379j–73/a - Carried out:
by adding at the end the following:
(2) Additional information.— Beginning with fiscal year 2026, the annual report under this subsection shall include— (A) the progress of the Food and Drug Administration in achieving the goals, and future plans for meeting the goals, including— (i) the number of Tier 1 OTC …
The section already has a provision under this letter or number, so it would have two.
- Not carried out:
by adding at the end of subsection (d) the following:
(4) Minutes of negotiation meetings.— (A) Public availability.— The Secretary shall make publicly available, on the public website of the Food and Drug Administration, robust written minutes of all negotiation meetings conducted under this subsection between the Food and Drug …
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: adding at the end of subsection (X) the following: QCONTENT.
This bill puts a provision under a letter or number this section already uses, so the section would have two. The law has probably changed since the bill was written.
§ 379j–73(a)–(c)
Start of § 379j–73 to (a)(2)(C)(ii) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (a)(2)(D) | (D) | (D) | ||
| the progress of the Food and Drug Administration in allowing nonclinical testing alternatives to animal testing for the consideration of sunscreen active ingredients. | the progress of the Food and Drug Administration in allowing nonclinical testing alternatives to animal testing for the consideration of sunscreen active ingredients. | |||
| (a)(3) | (3) Confidentiality | (3) Confidentiality | ||
| Nothing in paragraph (2) shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 331(j) of this title or section 1905 of title 18 or that is subject to withholding under section 552(b)(4) of title 5. | Nothing in paragraph (2) shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 331(j) of this title or section 1905 of title 18 or that is subject to withholding under section 552(b)(4) of title 5. | |||
| (a)(2) | (2) [inserted: Additional information.—] | |||
| [inserted: Beginning with fiscal year 2026, the annual report under this subsection shall include—] | ||||
| (a)(2)(A) | (A) [inserted: ] | |||
| [inserted: the progress of the Food and Drug Administration in achieving the goals, and future plans for meeting the goals, including—] | ||||
| (a)(2)(A)(i) | (i) [inserted: ] | |||
| [inserted: the number of Tier 1 OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;] | ||||
| (a)(2)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: the number of Tier 2 OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;] | ||||
| (a)(2)(A)(iii) | (iii) [inserted: ] | |||
| [inserted: the number of specified safety OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;] | ||||
| (a)(2)(A)(iv) | (iv) [inserted: ] | |||
| [inserted: the number of generally recognized as safe and effective finalization OTC monograph order requests for which a proposed order was issued, and the number of such requests for which a final order was issued, in the previous fiscal year;] | ||||
| (a)(2)(A)(v) | (v) [inserted: ] | |||
| [inserted: the average timeline for processing OTC monograph order requests, in the aggregate and by submission type, in the previous fiscal year; and] | ||||
| (a)(2)(A)(vi) | (vi) [inserted: ] | |||
| [inserted: postmarket safety activities with respect to OTC monograph drugs, including—] | ||||
| (a)(2)(A)(vi)(I) | (I) [inserted: ] | |||
| [inserted: collecting, developing, and reviewing safety information on OTC monograph drugs, including adverse event reports;] | ||||
| (a)(2)(A)(vi)(II) | (II) [inserted: ] | |||
| [inserted: developing and using improved analytical tools, adverse event data-collection systems, including information technology systems, to assess potential safety problems, including access to external databases; and] | ||||
| (a)(2)(A)(vi)(III) | (III) [inserted: ] | |||
| [inserted: activities under section 760; and] | ||||
| (a)(2)(B) | (B) [inserted: ] | |||
| [inserted: information regarding registration of OTC monograph drug facilities and contract manufacturing organization facilities and payment of registration fees by such facilities, including—] | ||||
| (a)(2)(B)(i) | (i) [inserted: ] | |||
| [inserted: the OTC monograph drug facilities and contract manufacturing organization facilities that were first registered under section 510(c) or 510(i) in the fiscal year; and] | ||||
| (a)(2)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: for each OTC monograph drug facility and contract manufacturing organization facility that was assessed a facility fee under section 744M(a) in the fiscal year, whether the facility paid such fee.] | ||||
| (a)(3) | (3) [inserted: Confidentiality.—] | |||
| [inserted: Nothing in paragraph (2) shall be construed to authorize the disclosure of information that is prohibited from disclosure under section 301(j) of this Act or section 1905 of title 18, United States Code, or that is subject to withholding under section 552(b)(4) of title 5, United States Code.] | ||||
| (b) | (b) Fiscal report | (b) Fiscal report | ||
| Not later than 120 calendar days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year. | Not later than 120 calendar days after the end of each fiscal year for which fees are collected under this subpart, the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected for such fiscal year. | |||
| (c) | (c) Public availability | (c) Public availability | ||
| The Secretary shall make the reports required under subsections (a) and (b) available to the public on the internet website of the Food and Drug Administration. | The Secretary shall make the reports required under subsections (a) and (b) available to the public on the internet website of the Food and Drug Administration. | |||
Rest of § 379j–73 unchanged